
Exagen Inc. – NASDAQ:XGN
Exagen stock price today
Exagen stock price monthly change
Exagen stock price quarterly change
Exagen stock price yearly change
Exagen key metrics
Market Cap | 86.51M |
Enterprise value | 13.44M |
P/E | -0.85 |
EV/Sales | 0.20 |
EV/EBITDA | -0.20 |
Price/Sales | 0.63 |
Price/Book | 0.97 |
PEG ratio | 0.01 |
EPS | -1.09 |
Revenue | 55.73M |
EBITDA | -16.69M |
Income | -19.36M |
Revenue Q/Q | 28.36% |
Revenue Y/Y | 16.70% |
Profit margin | -109.32% |
Oper. margin | -105.42% |
Gross margin | 44.38% |
EBIT margin | -105.42% |
EBITDA margin | -29.95% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeExagen stock price history
Exagen stock forecast
Exagen financial statements
$5
Potential downside: -48.24%
Analysts Price target
Financials & Ratios estimates
Jun 2023 | 14.13M | -5.01M | -35.46% |
---|---|---|---|
Sep 2023 | 13.41M | -5.41M | -40.36% |
Dec 2023 | 13.76M | -5.57M | -40.49% |
Mar 2024 | 14.41M | -3.36M | -23.31% |
Payout ratio | 0% |
---|
2019 | 2.11% |
---|---|
2020 | |
2021 | |
2022 | |
2023 |
Jun 2023 | 64178000 | 32.27M | 50.29% |
---|---|---|---|
Sep 2023 | 60928000 | 33.42M | 54.86% |
Dec 2023 | 56944000 | 34.25M | 60.15% |
Mar 2024 | 50808000 | 30.81M | 60.65% |
Jun 2023 | -10.15M | -322K | -10.24M |
---|---|---|---|
Sep 2023 | -2.90M | -2K | -108K |
Dec 2023 | 8.34M | -84K | -220K |
Mar 2024 | -9.04M | -86K | -100K |
Exagen alternative data
Aug 2023 | 199 |
---|---|
Sep 2023 | 199 |
Oct 2023 | 199 |
Nov 2023 | 199 |
Dec 2023 | 199 |
Jan 2024 | 199 |
Feb 2024 | 199 |
Mar 2024 | 174 |
Apr 2024 | 174 |
May 2024 | 174 |
Jun 2024 | 174 |
Jul 2024 | 174 |
Exagen other data
Period | Buy | Sel |
---|---|---|
Feb 2024 | 0 | 6738 |
Mar 2024 | 0 | 12784 |
May 2024 | 40401 | 0 |
Nov 2024 | 46603 | 200000 |
Patent |
---|
Application Filling date: 12 May 2022 Issue date: 1 Sep 2022 |
Application METHODS FOR DIAGNOSING, PROGNOSING AND MONITORING TREATMENT FOR THROMBOSIS IN SUBJECTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS Filling date: 5 Apr 2021 Issue date: 22 Jul 2021 |
Quarter | Transcript |
---|---|
Q1 2024 13 May 2024 | Q1 2024 Earnings Call Transcript |
Q4 2023 18 Mar 2024 | Q4 2023 Earnings Call Transcript |
Q3 2023 20 Nov 2023 | Q3 2023 Earnings Call Transcript |
Q2 2023 7 Aug 2023 | Q2 2023 Earnings Call Transcript |
Insider | Compensation |
---|---|
Mr. Fortunato Rocca (1961) Chief Executive Officer, Pres & Director | $1,080,000 |
Mr. Kamal Adawi M.S., MBA (1979) Chief Financial Officer & Corporation Sec. | $620,300 |
Dr. Debra Jeske Zack (1957) Chief Medical Officer | $576,660 |
-
What's the price of Exagen stock today?
One share of Exagen stock can currently be purchased for approximately $9.66.
-
When is Exagen's next earnings date?
Unfortunately, Exagen's (XGN) next earnings date is currently unknown.
-
Does Exagen pay dividends?
No, Exagen does not pay dividends.
-
How much money does Exagen make?
Exagen has a market capitalization of 86.51M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 15.33% to 52.55M US dollars.
-
What is Exagen's stock symbol?
Exagen Inc. is traded on the NASDAQ under the ticker symbol "XGN".
-
What is Exagen's primary industry?
Company operates in the Healthcare sector and Medical - Diagnostics & Research industry.
-
How do i buy shares of Exagen?
Shares of Exagen can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Exagen's key executives?
Exagen's management team includes the following people:
- Mr. Fortunato Rocca Chief Executive Officer, Pres & Director(age: 64, pay: $1,080,000)
- Mr. Kamal Adawi M.S., MBA Chief Financial Officer & Corporation Sec.(age: 46, pay: $620,300)
- Dr. Debra Jeske Zack Chief Medical Officer(age: 68, pay: $576,660)
-
How many employees does Exagen have?
As Jul 2024, Exagen employs 174 workers.
-
When Exagen went public?
Exagen Inc. is publicly traded company for more then 5 years since IPO on 19 Sep 2019.
-
What is Exagen's official website?
The official website for Exagen is exagen.com.
-
Where are Exagen's headquarters?
Exagen is headquartered at 1261 Liberty Way, Vista, CA.
-
How can i contact Exagen?
Exagen's mailing address is 1261 Liberty Way, Vista, CA and company can be reached via phone at +7 605601501.
-
What is Exagen stock forecast & price target?
Based on 1 Wall Street analysts` predicted price targets for Exagen in the last 12 months, the avarage price target is $5. The average price target represents a -48.24% change from the last price of $9.66.
Exagen company profile:

Exagen Inc.
exagen.comNASDAQ
174
Medical - Diagnostics & Research
Healthcare
Exagen Inc. develops and commercializes various testing products based on its cell-bound complement activation products technology under the AVISE brand in the United States. It enables rheumatologists to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus that measures activation of the complement system by quantifying the level of B-cell C4d and erythrocyte bound C4d in the patient's blood; and AVISE APS, which consists of a panel of autoantibody tests that aids in the diagnosis and management of APS. In addition, it provides AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody and associated vasculitis; AVISE Anti-CarP test, which identifies RA patients with severe disease; and AVISE PC4d to measure platelet- bound C4d. Further, the company offers AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop novel patented biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.
Vista, CA 92081
CIK: 0001274737
ISIN: US30068X1037
CUSIP: 30068X103